[Diabetic neuropathies].
Peripheral nerve involvement is a frequent complication of type 1 and type 2 diabetes, and can induce major disability. Almost all types of clinical or electrophysiological disturbances may be present: mononeuropathy involving cranial nerves or a limb; multiple mononeuropathy; proximal acute radiculopathy; distal, symmetric, sensory polyneuropathy; autonomic neuropathy. Physiopathology intricates probably several mechanisms but metabolic dysregulation and ischemia are mainly involved. Despite numerous controlled clinical trials no treatment has demonstrated efficacy for peripheral neuropathy, excepting the optimization of diabetes equilibrium. However, symptomatic treatments are available, particularly for the management of neuropathic pain.
Azulay
J P
JP
Service de neurologie et maladies neuromusculaires Hôpital de La Timone 13 385 Marseille. jazulay@ap-hm.fr
Pouget
J
J
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003929:Diabetic Neuropathies / Q000145:classification / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D004311:Double-Blind Method; D004594:Electrophysiology; D000077206:Gabapentin; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D019787:Linoleic Acid / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D011379:Prognosis; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003509:Cyclohexanecarboxylic Acids; D016756:Immunoglobulins, Intravenous; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D019787:Linoleic Acid